GTCR to acquire Zentiva from Advent.

GTCR, a private equity firm, agreed to acquire Zentiva, a generics pharmaceutical company, from Advent, a private equity firm. Financial terms were not disclosed. "Advent has been an exceptional partner in Zentiva's transformation journey. Their commitment to investing in our capabilities, pipeline, and manufacturing base has been instrumental in our growth and in ensuring we can better serve millions of patients across Europe. As we move forward with GTCR, we are excited to build on this momentum to ensure continued growth and expand access to high-quality, affordable medicines," Steffen Saltofte, Zentiva CEO.